HR0156 100TH GENERAL ASSEMBLY

HR0156 LRB100 10139 MST 21975 r

HOUSE RESOLUTION

WHEREAS, Fibromuscular dysplasia (FMD) is a disease that causes abnormal cell growth of the arterial wall; it can lead to areas of narrowing, beading, aneurysms, and dissections of the arterial wall; and

WHEREAS, Until recently, there has been very little progress in understanding the disease since it was first diagnosed in 1938; there is no known cause or cure for the disease and there are no set protocols to treat the disease; and

WHEREAS, FMD has always been considered and is still classified as a rare disease; many researchers now believe FMD is an under-diagnosed disease; some of the data suggest that 4-5% of the population may be affected by the disease; and

WHEREAS, Ninety percent of the patients affected by FMD are women, but men and children are also afflicted; there are different classifications of FMD; the two most common types are medial fibroplasia and intimal fibroplasia; unlike the adult population, children tend to be diagnosed with intimal fibroplasia, which can be more aggressive; some patients present with both types of the disease; there is no understanding of why there are differences; and

WHEREAS, Individuals and families affected by fibromuscular dysplasia often experience problems such as a sense of isolation, difficulty in obtaining accurate and timely diagnosis, and optimal treatment options; and

WHEREAS, The Fibromuscular Dysplasia Society of America (FMDSA) was founded in March of 2003; over the past 14 years, this association has been active and successful with many programs, including public and physician awareness, patient support, and engaging with researchers from around the world; and

WHEREAS, The FMDSA is funding the United States Registry for Fibromuscular Dysplasia; previously it was thought that 75% of FMD cases affected the renal arteries, but recent data has proven that to be inaccurate; it is also very common to have a 5-year delay from onset of symptoms to diagnosis; and

WHEREAS, There is still much needed awareness and research of the disease; FMD patients present with many of the same complaints as other patients with more common conditions, such as hypertension, headaches, and dizziness; others present with TIA or stroke, dissection of an artery, aneurysm, swooshing noise in the ear, and renal infarction; children can present with basic symptoms such as high blood pressure, headaches, insomnia, fatigue, and abdominal pain; misdiagnoses of FMD can lead to severe consequences and disability; and

WHEREAS, During the month of May each year, the FMDSA organizes a global observance of the issues associated with fibromuscular dysplasia; patients, medical professionals, and researchers join together to focus attention on fibromuscular dysplasia as a public health issue; therefore, be it

RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE HUNDREDTH GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that we designate May of 2017 as "Fibromuscular Dysplasia Awareness Month" in the State of Illinois; and be it further

RESOLVED, That a suitable copy of this resolution be presented to the Fibromuscular Dysplasia Society of America as an expression of our esteem and respect.